Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$196.4M
-28.0% from 2023
Prescriptions
1.3M
$153.30 per claim
Patients
447K
171,445 prescribers
Total spending, 2024
$196.5M
$439.86 per patient
Medicare prescription drug plans paid $196.4M for Wixela Inhub in 2024, for 1,281,293 prescriptions and refills to 446,560 patients (down 28.0% from 2023). The average cost per claim was $153.30.
California had the highest Medicare cost for Wixela Inhub in 2024: $43.3M for 237,558 claims, followed by Florida ($13.0M).
Jahaira L Serrano Dominguez, pulmonary disease in Arecibo, PR, had the highest Medicare cost for Wixela Inhub in 2024: 1,629 claims costing $344K.
Wixela Inhub is made by Viatris Inc. (VTRS), listed in the Medicare spending data as Mylan.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Jahaira L Serrano Dominguez Arecibo, PR | Pulmonary Disease | 1,629 | 319 | $344K |
| Axel W Velez Santiago San German, PR | Pulmonary Disease | 1,338 | 376 | $265K |
| Carlos R Alcala Marquez |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 150,184 | 1,094,049 | 351,977 | $326.7M |
| 2023 | 139,936 | 956,867 | 320,411 | $272.9M |
| 2024 | 171,445 | 1,281,293 | 446,560 | $196.4M |
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 992 |
| 206 |
| $154K |
| Jorge Sanchez-Masiques Miami, FL | Pulmonary Disease | 2,187 | 510 | $151K |
| Ashesh D Desai Conroe, TX | Pulmonary Disease | 431 | 204 | $134K |
| Armando O Cardona-Ramirez Mayaguez, PR | Pulmonary Disease | 838 | 196 | $133K |
| Carlos N Montalvo Bonilla Arecibo, PR | Internal Medicine | 681 | 164 | $123K |
| Luis C Torrellas Ruiz Humacao, PR | Pulmonary Disease | 647 | 131 | $121K |
| Noel Totti III Hato Rey, PR | Pulmonary Disease | 795 | 219 | $110K |
| Eldrige F Pineda Washington, DC | Internal Medicine | 509 | 182 | $107K |
| Samuel Suarez Baez San Juan, PR | Pulmonary Disease | 687 | 162 | $100K |
| Sheila A Mayo-Olano Upper Marlboro, MD | Pulmonary Disease | 418 | 140 | $90K |
| Samay A Dalal Denver, CO | Internal Medicine | 286 | 128 | $89K |
| Fiona F Meller Azrieli Halethorpe, MD | Internal Medicine | 329 | 136 | $89K |
| Pedro J Monroig Quiles San Juan, PR | Internal Medicine | 603 | 202 | $86K |
| Natanyah R Siegel Kennesaw, GA | Pulmonary Disease | 450 | 117 | $85K |
| Ian Kirkpatrick Talihina, OK | Family Practice | 408 | 72 | $81K |
| Christina H Lee Los Angeles, CA | Allergy/ Immunology | 264 | 117 | $79K |
| Edward Len Bethesda, MD | Hospitalist | 381 | 129 | $71K |
| Richard M Bradburne Riverside, CA | Internal Medicine | 265 | 109 | $69K |
| Andrew J Schissler Upper Marlboro, MD | Pulmonary Disease | 348 | 143 | $67K |
| Dung A Nguyen Fontana, CA | Internal Medicine | 226 | 100 | $66K |
| Robert R Rusher Duluth, GA | Pulmonary Disease | 470 | 99 | $66K |
| Beau V Duwe San Diego, CA | Internal Medicine | 463 | 110 | $65K |
| Margaret L Kurohara Bellflower, CA | Allergy/ Immunology | 215 | 91 | $65K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Mylan VTRS | 1,281,804 | $196.5M |